2345 related articles for article (PubMed ID: 33479026)
21. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
22. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
23. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
24. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
[TBL] [Abstract][Full Text] [Related]
25. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
Tosi A; Cappellesso R; Dei Tos AP; Rossi V; Aliberti C; Pigozzo J; Fabozzi A; Sbaraglia M; Blandamura S; Del Bianco P; Chiarion-Sileni V; Rosato A
J Exp Clin Cancer Res; 2021 May; 40(1):154. PubMed ID: 33947438
[TBL] [Abstract][Full Text] [Related]
26. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
27. Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.
Cao Q; Wang W; Zhou M; Huang Q; Wen X; Zhao J; Shi S; Geng K; Li F; Hatakeyama H; Xu C; Piwnica-Worms D; Peng W; Zhou D; Sood AK; Li C
Nanomedicine; 2020 Apr; 25():102169. PubMed ID: 32059873
[TBL] [Abstract][Full Text] [Related]
28. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
Masaoutis C; Kokkali S; Theocharis S
Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma.
Zeng Q; Yang J; Ji J; Wang P; Zhang L; Yan G; Wu Y; Chen Q; Liu J; Zhang G; Wang X
Oncoimmunology; 2022; 11(1):2061396. PubMed ID: 35402079
[TBL] [Abstract][Full Text] [Related]
31. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
32. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
[No Abstract] [Full Text] [Related]
33. Near-Infrared-II Nanoparticles for Vascular Normalization Combined with Immune Checkpoint Blockade via Photodynamic Immunotherapy Inhibit Uveal Melanoma Growth and Metastasis.
Zheng X; Shi Y; Tang D; Xiao H; Shang K; Zhou X; Tan G
Adv Sci (Weinh); 2023 Dec; 10(35):e2206932. PubMed ID: 37939284
[TBL] [Abstract][Full Text] [Related]
34. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
35. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
36. Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy.
Lou J; Aragaki M; Bernards N; Chee T; Gregor A; Hiraishi Y; Ishiwata T; Leung C; Ding L; Kitazawa S; Koga T; Sata Y; Ogawa H; Chen J; Kato T; Yasufuku K; Zheng G
Biomaterials; 2023 Jan; 292():121918. PubMed ID: 36442438
[TBL] [Abstract][Full Text] [Related]
37. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
38. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract][Full Text] [Related]
39. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
40. Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.
Sun Z; Chu Y; Xiao J; Yang Y; Meng F; Wang X; Dong Y; Zhu J; Wu Y; Qin L; Ke Y; Liu B; Liu Q
J Transl Med; 2023 Sep; 21(1):619. PubMed ID: 37700338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]